Regeneron

News

Amgen, AZ's Tezspire challenges Dupixent in nasal polyps

Amgen and AstraZeneca's fast-growing asthma drug Tezspire is now poised to take on rival Dupixent in chronic rhinosinusitis with nasal polyps.

News

Regeneron's Libtayo stakes out new territory in skin cancer

Regeneron's Libtayo has become the first checkpoint inhibitor to be cleared by the FDA as an adjuvant treatment for cutaneous squamous cell carcinoma.

R&D

Interview at LSX 25 with Alison Fenney feature

Why Regeneron is giving away sequencing “for free”, with Ali...

Alison Fenney, executive director of strategic partnerships and business operations at Regeneron Genetics Center, discusses free genetic sequencing.

News

Regeneron drug on track to be second FOP treatment

There is only one approved drug for ultra-rare disease FOP on the market, but Regeneron is hoping to add a second.

News

Regeneron preps filings for myasthenia gravis drug

Regeneron could be just a few months away from filing for a myasthenia gravis drug that can be dosed just once every three months.

News

Regeneron gets long-awaited FDA okay for myeloma drug

Regeneron's bid to join the crowded US market for BCMA-targeted bispecific antibodies for multiple myeloma has finally been realised.

Amgen, AZ's Tezspire challenges Dupixent in nasal polyps

Regeneron's Libtayo stakes out new territory in skin cancer

Why Regeneron is giving away sequencing “for free”, with Ali...

Regeneron drug on track to be second FOP treatment

Regeneron preps filings for myasthenia gravis drug

Regeneron gets long-awaited FDA okay for myeloma drug

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

Regeneron

Editor's Picks